Atopic Dermatitis

The FDA has decided to extend the priority review period for abrocitinib, a JAK1 inhibitor or moderate to severe atopic dermatitis in patients 12 years and older.

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

In this video interview, Linda Stein Gold, MD, discusses her recent presentation at the Inaugural SISD regarding using topicals for atopic dermatitis.

Some strains appear to reduce risk in pregnant women and infants.

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

An investigation examines which infants might require screening before peanut introduction.

Incyte announces the FDA has accepted the NDA for ruxolitinib cream for priority review. Ruxolitinib cream is a topical selective janus kinase (JAK)1/JAK2 inhibitor intended for the treatment of atopic dermatitis.

The limited armamentarium of systemic therapies for atopic dermatitis has already been expanded with the approval of dupilumab. Forthcoming systemic therapies are expected to include a new biologic and three new Janus kinase (JAK) inhibitors.

Several universal gaps in diagnosis and treatment of atopic dermatitis (AD) as well as real-world interventions for improvement are the focus of a ground-breaking report.

New treatments for atopic dermatitis offer more options with favorable safety and efficacy.

Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.

Adam Friedman, MD, FAAD, outlined his five rules to ensure an effective atopic dermatitis management plan and discussed the current treatments available.

Arcutis Biotherapeutics announces the commencement of two identical phase 3 clinical trials evaluating topical PDE4 inhibitor roflumilast cream in patients with mild-to-moderate atopic dermatitis.

A vast majority of patients with atopic dermatitis (AD) are satisfied with dupilumab (Dupixent, Sanofi and Regeneron) treatment, according to research presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.

A new innovative report identifies gaps and offers solutions for improving quality of care in atopic dermatitis (AD).

New study data shows that in adults with atopic dermatitis, dupilumab has performed as expected, with continued efficacy and no new safety signals.

Infants with eczema may require different approaches to preventing food allergies, including early introduction of peanuts to increase oral exposure to allergens before skin exposure.

Dupilumab and JAK inhibitors are leading the way in atopic dermatitis treatment, but there are numerous clinical trials of both new biologics and new small molecule drugs, and future treatment regimens likely will utilize both.

The first and only atopic dermatitis conference, Revolutionizing Atopic Dermatitis (RAD), will be hosting its third event, in a virtual format.

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.

A recent review reveals older adults are underrepresented in trials investigating systemic immunomodulators as a treatment for atopic dermatitis.

Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.

Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.

In clinical trials, most patients treated with tralokinumab maintained 75% reductions in EASI scores for one year.

Vehicles for topical atopic dermatitis treatments deliver benefits that promote barrier restoration and enhance innate immune defenses, a review suggests.

Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.

The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.

The U.S. Food and Drug administration has accepted the Biologics License Application for tralokinumab (LEO Pharma) for moderate-to-severe atopic dermatitis and is expected to make a decision in the second quarter of 2021.

Researchers of a recent systematic review and meta-analysis examine how dupilumab compares to older systemic treatments for atopic dermatitis, including methotrexate, cyclosporine and azathioprine.